Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects
Clinical Pharmacology in Drug Development · 2025-08 · 14 (8) · 605-613
DOI: 10.1002/cpdd.1520 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 14.05.2025. Verfasst von Martha Gonzalez und 5 weiteren Autor:innen. Beteiligte Einrichtung: HUTCHMED International Corporation, Florham Park, NJ, USA. Hauptthemen laut MEDLINE: Rifampin, Itraconazole, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Inducers. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cytochrome P450 (CYP) 3A plays a significant role in fruquintinib metabolism in vitro. This 2‐part, 2‐period fixed‐sequence study investigated the impact of CYP3A inhibition (itraconazole) and CYP3A induction (rifampin) on the pharmacokinetics (PK) of fruquintinib and M11, its main metabolite. Fourteen healthy subjects in each part received a single dose of fruquintinib 5 mg alone in Period 1 and with itraconazole (Part A) or rifampin (Part B) in Period 2 under fasted conditions. Itraconazole or rifampin was administered daily 4 or 7 days before coadministration, respectively; administration of both continued throughout the PK sampling period. PK samples were collected before dosing and over 168 hours after fruquintinib dosing. Coadministration with itraconazole resulted in an increase of fruquintinib systemic exposure, determined by area under the plasma concentration‐time curves (AUCs) by approximately 10%. Decreases in M11 AUCs and maximum plasma concentration (C max ) ranged from 44% to 55% but were not considered clinically meaningful. Rifampin reduced fruquintinib C max and AUCs by 12% and 65%, respectively. Rifampin had a marginal effect on M11 AUCs and increased M11 C max by 2.3‐fold. Data support that concomitant use of fruquintinib with potent CYP3A inducers of rifampin‐like potency should be avoided, but no dose adjustment is recommended when coadministered with CYP3A inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- HUTCHMED International Corporation, Florham Park, NJ, USA.
- Takeda Development Center Americas, Inc. (TDCA), Cambridge, MA, USA.
Zitieren
APA
Gonzalez, M., Yang, Z., Schelman, W. R., Zhou, X., Gupta, N., & Chien, C. (2025). Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects. Clinical Pharmacology in Drug Development, 14(8), 605-613. https://doi.org/10.1002/cpdd.1520
Vancouver
Gonzalez M, Yang Z, Schelman WR, Zhou X, Gupta N, Chien C. Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects. Clinical Pharmacology in Drug Development. 2025;14(8):605-613. doi:10.1002/cpdd.1520
BibTeX
@article{Gonzalez2025,
author = {Gonzalez, Martha and Yang, Zhao and Schelman, William R and Zhou, Xiaofei and Gupta, Neeraj and Chien, Caly},
title = {Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
volume = {14},
number = {8},
pages = {605--613},
doi = {10.1002/cpdd.1520}
}
EUVIMED